FDA Issues Draft Guidance Integrating Real-World Data and AI for Enhanced Cell and Gene Therapy Postmarket Surveillance
核心洞察
The FDA released draft guidance in September 2025 outlining methods for capturing safety and efficacy data for cell and gene therapy (搜索) products after market approval, emphasizing the use of real-world data and artificial intelligence.
The guidance addresses the unique monitoring challenges of CGTs, which require long-term follow-up studies potentially lasting 15 years or more, particularly for pediatric patients who must be followed into adulthood.
Real-world data sources can be leveraged to train AI and natural language processing models for developing computable phenotypes, while registries and decentralized data collection models are recommended to optimize long-term surveillance.
The U.S. Food and Drug Administration has released comprehensive draft guidance outlining innovative approaches for postmarket surveillance of cell and gene therapy (搜索) products, emphasizing the integration of real-world data and artificial intelligence technologies to enhance long-term safety and efficacy monitoring.
Released in September 2025 through the Center for Biologics Evaluation and Research (搜索), the draft guidance titled "Postapproval Methods to Capture Safety and Efficacy Data for Cell and Gene Therapy (搜索) Products" provides nonbinding recommendations for effectively gathering data on CGT product performance after market approval. This guidance represents a critically important step for the biopharmaceutical industry, particularly for companies involved in CGT manufacturing and development.
Addressing Unique CGT Monitoring Challenges
The guidance acknowledges the distinctive characteristics of cell and gene therapies that necessitate specialized postapproval monitoring approaches. Because CGT products have the potential for long-lasting effects, and clinical trials supporting their approval typically involve a limited number of participants, postapproval monitoring is essential for understanding long-term outcomes and guiding safe clinical use.
Observational studies for these therapies often need to be long-term, potentially lasting 15 years or more, especially for treatments administered to pediatric patients who must be followed into adulthood. The guidance focuses on leveraging modern data infrastructure to balance premarket and postmarket data collection, addressing the inherent challenges of monitoring therapies with potentially permanent effects.
Real-World Data Integration and AI Applications
A key element of the guidance is its extensive discussion on utilizing real-world data sources to derive real-world evidence. For sponsors, especially those with small patient pools common in CGT development, maximizing the utility of existing data is vital. While administrative medical claims, vital statistics, and electronic health records are not primarily designed for product evaluation, they can be utilized if sponsors account for constraints such as fragmented data and inadequate medical coding terminology.
The FDA explains that RWD sources can be applied to key postapproval activities, including assessing rates of clinical outcomes, determining background rates of adverse outcomes such as cardiovascular complications (搜索) or malignancies (搜索), and observing CGT outcomes across multiple patient populations. Significantly, the guidance notes that RWD can be used for training artificial intelligence and natural language processing machine-learning models to develop computable phenotypes for safety or effectiveness outcomes.
This integration of advanced data processing techniques underscores a commitment to rigorous data quality and necessitates that sponsors establish robust data governance structures to ensure the integrity and confidentiality of RWD.
Registry-Based Surveillance and Decentralized Models
The guidance highlights registries as organized systems that collect standardized, curated, longitudinal clinical data over time, offering distinct advantages over less structured data sources such as medical claims databases. Registries are particularly relevant for postapproval surveillance of CGTs and support the assessment of long-term durability of response, monitoring of growth and developmental milestones in pediatric recipients, and surveillance for malignancies (搜索).
When using registries, the FDA emphasizes that sponsors must be mindful of recruitment challenges to ensure the registry remains representative of the target patient population. The guidance additionally advocates for using decentralized models for data collection, similar to those used in decentralized clinical trials.
This approach involves conducting study-related activities outside the traditional clinical site, thereby improving generalizability, optimizing efficiency, and enhancing patient convenience and retention. Because treatment with CGTs often requires many years of follow-up, reducing the burden of travel by utilizing local healthcare professionals, facilities, and telemedicine visits is essential for ensuring high completion rates in long-term follow-up studies.
Comprehensive Monitoring Framework
The draft guidance provides detailed instructions on how sponsors should design postapproval monitoring plans tailored to the unique characteristics of cell and gene therapy (搜索) products. It highlights the need for ongoing evaluation of potential risks associated with these therapies, including delayed adverse events or changes in product performance over time.
The FDA also addresses considerations for manufacturing consistency and strategies to mitigate risks related to variability in production processes. The agency encourages collaboration between sponsors and regulatory bodies to refine monitoring practices as scientific understanding evolves, emphasizing the importance of long-term follow-up studies, robust adverse event reporting systems, and consistent product quality assessments.